Lazard Asset Management
SRNE

Lazard Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lazard Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,229
Closed -$35K – 2634
2022
Q4 		$35K Buy
+40,229
New +$53.4K ﹤0.01% 1963
2022
Q3 		– Sell
-39,498
Closed -$79K – 2635
2022
Q2 		$79K Buy
+39,498
New +$68.3K ﹤0.01% 1608
2020
Q4 		– Sell
-1,787
Closed -$19K – 2033
2020
Q3 		$19K Sell
1,787
-24,809
-93% -$227K ﹤0.01% 1433
2020
Q2 		$167K Sell
26,596
-2,413
-8% -$9.24K ﹤0.01% 942
2020
Q1 		$53K Buy
+29,009
New +$83.6K ﹤0.01% 1157

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $177M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $5.91B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.01B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return